<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Conformation-X Therapeutics, LLC 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=45274></link><description><![CDATA[Conformation-X Therapeutics, LLC 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 05:34:42 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2024/04/112_1028147215_20240404141835_7845573296.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline]]></title><link>https://www.newswire.co.kr/newsRead.php?no=987279</link><description><![CDATA[CANTON, Mass.--(Business Wire/Korea Newswire)--Conformation-X Therapeutics, LLC , an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 ...]]></description><pubDate>Thu, 04 Apr 2024 14:35:00 +0900</pubDate></item><item><title><![CDATA[컨포메이션-X 테라퓨틱스, 1350만달러 이상의 자금 조달로 혁신적 면역 항암 파이프라인 가속]]></title><link>https://www.newswire.co.kr/newsRead.php?no=987280</link><description><![CDATA[캔턴, 매사추세츠--(Business Wire/뉴스와이어)--면역 항암에 중점을 둔 약물 개발 회사인 컨포메이션-X 테라퓨틱스 (Conformation-X Therapeutics, LLC)가 초과 청약된 365만달러 규모의 펀딩을 마감하며 개시 후 총 모금액이 1350만달러를 넘어섰다고 오늘 발표했다. 회사는 HHLA2 및 IL18BP 프로그램에 대한 성공적인 생체 외(ex vivo) 및 생체 내(in vivo) 개념 증명 연구를 공개하여 자사의 주요 자산을 선보임으로써 ...]]></description><pubDate>Thu, 04 Apr 2024 14:35:00 +0900</pubDate></item></channel></rss>